Different cytokines are now therapeutic targets in asthma with different treatments on the market targeting IL5 or IL4 and IL13 receptor and other products in development that comprise CXCR2 antagonists or low molecular weight chemicals that antagonize CCL11 receptor, cysteine-cysteine chemokine receptor-3 (CCR3) [19–21]. The gene discussed is CCR3; the disease is asthma.